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Abstract
Background: Statin-related skeletal muscle disorders range from benign myalgias – such as non-
specific muscle aches or joint pains without elevated serum creatinine kinase (CK) concentration
– to true myositis with >10-fold elevation of serum CK, to rhabdomyolysis and myoglobinuria. The
genetic basis of statin-related muscle disorders is largely unknown. Because mutations in the COQ2
gene are associated with severe inherited myopathy, we hypothesized that common, mild genetic
variation in COQ2 would be associated with inter-individual variation in statin intolerance. We
studied 133 subjects who developed myopathy on statin monotherapy and 158 matched controls
who tolerated statins without incident or complaint.
Results: COQ2 genotypes, based on two single nucleotide polymorphisms (SNP1 and SNP2) and
a 2-SNP haplotype, all showed significant associations with statin intolerance. Specifically, the odds
ratios (with 95% confidence intervals) for increased risk of statin intolerance among homozygotes
for the rare alleles were 2.42 (0.99 to 5.89), 2.33 (1.13 to 4.81) and 2.58 (1.26 to 5.28) for SNP1
and SNP2 genotypes, and the 2-SNP haplotype, respectively.
Conclusion: These preliminary pharmacogenetic results, if confirmed, are consistent with the idea
that statin intolerance which is manifested primarily through muscle symptoms is associated with
genomic variation in COQ2 and thus perhaps with the CoQ10 pathway.
Background
Large clinical trials over the past two decades have une-
quivocally established the benefit of 3-hydroxy-3-methyl-
glutaryl coenzyme A (HMG CoA) inhibitors – or "statins"
– in the primary and secondary prevention of coronary
heart disease (CHD) [1]. Reduction of plasma low-density
lipoprotein (LDL) cholesterol with statins has revolution-
ized clinical cardiology; this family of drugs is generally
well-tolerated, easy to administer, and has very good
patient acceptance. However, the potential for adverse
effects exists. From clinical trials, the statin discontinua-
tion rate due to adverse events ranges between 1 and 5%
[1]. Frequently reported adverse effects include gastroin-
testinal complaints, rashes, dizziness, pruritus and head-
ache [2]. Statin-related skeletal muscle disorders range
from benign myalgias – such as non-specific muscle aches
or joint pains without elevated serum creatinine kinase
(CK) concentration – to true myositis with >10-fold eleva-
tion of serum CK [3]. The incidence of muscle aches and
pains with statin monotherapy ranges from 1 to 7%,
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whereas severe myopathy, defined as >10-fold elevation
of serum CK with muscle pains, weakness and tenderness,
occurs in up to 0.5% of patients [3]. Life-threatening rhab-
domyolysis with muscle necrosis and subsequent electro-
lyte alterations, myoglobinuria and renal failure is
extremely rare [4]. Rhabdomyolysis is frequently related
to use of a statin in combination with such agents as fibric
acid derivatives, cyclosporine, macrolide antibiotics or
antifungal agents [4].
Recently, genomic variations have been evaluated with
respect to inter-individual differences in response to statin
therapy, both in terms of LDL-lowering and clinical out-
comes [5]. A few studies have also reported associations
between polymorphisms in candidate genes and
decreased adherence to or increased discontinuation of
statin drugs [6]. However, the role of genetic polymor-
phisms in predicting adverse events associated with statin
use remains to be established. Potential candidate genes
whose products might be determinants of statin intoler-
ance include those encoding enzymes involved in drug
metabolism [6], mitochondrial function [7] or ubiquiti-
nation [8]. Ubiquinone, also known as coenzyme Q10
(CoQ10), is synthesized, together with mevalonate, by all
cells. In theory, inhibition of mevalonate synthesis by
statins reduces not only the biosynthesis of cholesterol
but also of CoQ10 [9]. Indeed, reduced CoQ10 concen-
trations have been suggested as a potential mechanism for
statin-induced myotoxicity [9]. A role for genetics as a
potential determinant was recently demonstrated in two
siblings with primary CoQ10 deficiency each of whom
was homozygous for a missense mutation in the COQ2
gene encoding para-hydroxybenzoate-polyprenyl trans-
ferase [10], which is the second enzyme in the CoQ10
biosynthetic pathway. Given the association of CoQ10
deficiency with statin-induced myotoxicity [11], we
hypothesized that genetic variation in COQ2 was associ-
ated with inter-individual variation in statin tolerability.
Results
Clinical and demographic data
Descriptive baseline clinical features of statin-intolerant
patients and controls are shown in Table 1. All study sub-
jects were self-identified as having European geographical
ancestry. Cases and controls were well matched for age,
sex, smoking status or treatment for diabetes, hyperten-
sion or hypothyroidism. There were no differences in
baseline serum C-reactive protein concentration. The pro-
portions of statins used that were atorvastatin, rosuvasta-
tin and all other statins were, respectively, 28%, 26% and
46% in the statin-intolerant group and 45%, 36% and
19% in the control group.
Two statin-intolerant patients had been hospitalized with
rhabdomyolysis: each developed CK > 10,000 U/L within
6 weeks of statin monotherapy and myoglobinuria and
transiently increased serum creatinine, but with eventual
return to normal limits of renal function. Compared with
control subjects, statin-intolerant patients had signifi-
cantly higher concentrations of serum CK both at baseline
Table 1: Baseline attributes of study subjects
statin-intolerant controls P-value
Number 133 158
percent female 36.6% 35.5% NS
age (years) 57.1 ± 12.1 55.9 ± 11.3 NS
current smoking 20.3% 21.8% NS
on treatment for diabetes 24.3% 19.7% NS
on treatment for hypertension 43.7% 39.2% NS
on treatment for hypothyroidism 13.2% 11.5% NS
serum thyrotropin (U/L) 4.4 ± 17.3 2.4 ± 2.7 NS
serum C-reactive protein (mg/dL) 5.0 ± 4.6 4.8 ± 5.7 NS
serum creatine kinase (U/L)
- highest recorded on treatment 621 ± 927 280 ± 426 <0.0001
- lowest recorded off treatment 175 ± 220 120 ± 120 0.0095
- elevated 5× upper normal limit 17.7% 2.5% <0.0001
- elevated 10× upper normal limit 5.9% 0.6% 0.009
serum asparagine transaminase (U/L)
- highest recorded on treatment 47.5 ± 32.1 40.9 ± 17.5 0.03
- lowest recorded off treatment 23.8 ± 8.7 23.5 ± 10.6 NS
- elevated 3× upper normal limit 2.9% 0% 0.03
serum alanine transfaminase (U/L)
- highest recorded on treatment 41.9 ± 26.7 38.1 ± 20.7 NS
- lowest recorded off treatment 32.3 ± 24.5 27.9 ± 15.4 NS
- elevated 3× upper normal limit 1.5% 0% NS
hospitalized with rhabdomyolysis 1.5% 0% <0.0001Lipids in Health and Disease 2007, 6:7 http://www.lipidworld.com/content/6/1/7
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and on treatment, with significantly higher proportions of
individuals with CK elevated 5- and 10-fold above the
upper normal limit. Compared with control subjects, sta-
tin-intolerant patients had significantly higher concentra-
tions of serum asparagine transaminase (AST) on
treatment but not at baseline, with significantly higher
proportions of individuals with AST elevated 3-fold above
the upper normal limit. No differences in alanine
transaminase (ALT) were seen. There was no systematic
correlation among individuals who had elevations in
both CK and AST (data not shown).
Genetic descriptors of study sample
COQ2 allele and genotype frequencies are shown in Table
2. The pairwise linkage disequilibrium correlation coeffi-
cient between alleles of SNP1 and SNP2 was 0.81 (P <
0.0001), indicating strong linkage disequilibrium. Maxi-
mal likelihood haplotype definitions and frequencies are
shown in Table 2. The most common haplotype was des-
ignated as "haplotype 1" and had an overall frequency of
0.62.
Genetic associations with statin intolerance
Results of genetic association analysis are shown in Table
3. For association analysis of statin-intolerance, COQ2
SNP genotypes were tested using both dominant and
recessive models for the minor allele. For association anal-
ysis, COQ2 haplotypes were collapsed into three groups,
based on the presence or absence of haplotype 1. Thus,
participants in this study had one of three possible diploid
summary haplotypes: 1/1, 1/X or X/X, where X refers to
any non-1 haplotype. For association analysis, two mod-
els were tested, namely dominant and recessive for the
non-1 haplotype alleles.
Under recessive models for each, the COQ2 SNP1 and
SNP2 genotypes, and also the 2-SNP haplotype all
showed significant associations with statin intolerance.
Specifically, the odds ratios (with 95% confidence inter-
vals [CIs]) for increased risk of statin intolerance among
homozygotes for the rare alleles were 2.42 (0.99 to 5.89),
2.33 (1.13 to 4.81) and 2.58 (1.26 to 5.28) for SNP1 and
SNP2 genotypes, and the 2-SNP haplotype, respectively.
Under dominant models for each, the COQ2 SNP1 and
SNP2 genotypes, and 2-SNP haplotypes were not associ-
ated with statin intolerance. There was no association
between any genotype and either continuous or discrete
CK, AST or ALT variables (data not shown). The subjects
with rhabdomyolysis were homozygous for the common
SNP alleles and also for haplotype 1.
Discussion
In this preliminary analysis of a small sample of subjects,
we found that genetic variation in COQ2, as defined by
two genotypes and a haplotype derived from the two most
informative SNPs of this gene, was significantly associated
Table 3: Genetic associations with statin-induced myopathy
Odds ratio (95% CI) P-value
SNP-1 A-dominant 1.19 (0.75 to 1.88) NS
A-recessive 2.42 (0.99 to 5.89) 0.047
SNP-2 G-dominant 1.10 (0.69 to 1.75) NS
G-recessive 2.33 (1.13 to 4.81) 0.019
haplotype non-1 dominant 1.08 (0.67 to 1.72) NS
non-1 recessive 2.58 (1.26 to 5.28) 0.007
Table 2: Genotype and allele frequencies
statin-intolerant controls
SNP-1 G/G 65 (48.9) 85 (53.8)
G/A 53 (40.0) 66 (41.8)
A/A 15 (11.1) 7 (4.4)
G 68.9 74.7
A 31.1 25.3
SNP-2 C/C 55 (41.4) 69 (43.7)
C/G 55 (41.4) 76 (48.1)
G/G 23 (17.3) 13 (8.2)
C 62.1 67.8
G 37.9 32.2
2-SNP haplotypes 1,1 54 (40.6) 67 (41.9)
1,2 9 (6.8) 17 (10.6)
1,3 0 2 (1.3)
1,4 45 (33.8) 60 (37.5)
2,2 1 (0.8) 1 (0.6)
2,4 9 (6.8) 5 (3.1)
3,3 1 (0.8) 0
3,4 1 (0.8) 0
4,4 13 (9.8) 8 (5.0)
1 60.9 66.5
2 7.5 7.5
3 1.1 0.6
4 30.4 25.3Lipids in Health and Disease 2007, 6:7 http://www.lipidworld.com/content/6/1/7
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with statin intolerance. Specifically, homozygotes for rare
alleles of SNP1, SNP2 and the 2-SNP haplotype – ~15%
of the study sample – had significantly increased odds of
statin intolerance, defined primarily through muscle
symptomatology. Significant clinical differences between
patients with statin intolerance and control subjects
included significantly elevated serum CK both on treat-
ment and at baseline, and elevated serum AST on treat-
ment only. Upon review, there is no clear evidence for the
use of other medications that could affect muscle func-
tion. Furthermore, the amount and intensity of exercise in
the two groups was not recorded, although it was unlikely
to have been significantly different.
Genetic determinants of statin intolerance include both
common SNPs and rare mutations. For instance, a study
conducted primarily in a sample of patients with statin-
induced myopathy ascertained through neurology clinics
indicated that up to 10% of statin-intolerant subjects were
heterozygous or homozygous for disease-causing muta-
tions in rare metabolic myopathies, namely carnitine
palmitoyl transferase II deficiency and McArdle disease
[7]. Furthermore, muscle biopsies from statin-intolerant
patients showed that about half had significant qualitative
abnormalities in mitochondrial and fatty acid metabo-
lism without a discrete molecular defect [7]. Such findings
are consistent with a biological basis for statin myopathy
that has a variety of genetic determinants. The findings
from the present study indicate that polymorphism in the
COQ2 gene may be one such cause out of many in the
general population. Mechanistic implication of the ubiq-
uinone pathway is further provided by a recent report of
altered ubiquinone levels in muscle biopsies from
patients on statins [12].
Some have questioned the clinical significance of statin-
related side effects. For instance, a recent systemic over-
view of randomized clinical trials on risks associated with
statin therapy appeared to show no excess of myalgias or
CK elevations in patients on statins compared to placebo
in 74,000 subjects involved in 35 trials [13]. However, the
translation of these findings from controlled clinical trials
to the "real world" of clinical practice is questionable.
There is little doubt that most clinicians who prescribe sta-
tin drugs regularly would be aware of these side effects
and would consider them to be an important clinical
problem that interferes with statin compliance for many
patients.
While our findings support a relationship between COQ2
genetic variation and statin intolerance, limitations of this
study, as with most association studies [14] include: 1)
small sample size; 2) absence of a replication sample; 3)
absence of a functional consequence of the genetic vari-
ants tested; and 4) absence of genetic associations with
intermediate quantitative traits, specifically CK on treat-
ment or muscle pathology. Furthermore, the markers
studied may have been in linkage disequilibrium with
unmeasured functional marker in COQ2 or in some prox-
imal gene that was the actual mechanistic basis of the
association.
Conclusion
Thus, in this preliminary analysis, we found that genetic
variation in COQ2, as defined by two genotypes and a
haplotype derived from the two most informative SNPs of
this gene, was associated with increased odds of statin
intolerance, defined primarily through muscle symp-
tomatology. Clearly, additional mechanistic and genetic
studies are required to confirm these observations. But
these preliminary pharmacogenetic results are consistent
with the idea that statin intolerance which is manifested
primarily through muscle symptoms is associated with
genomic variation in COQ2 and thus perhaps with the
CoQ10 pathway.
Methods
Study subjects
We studied 291 patients from a single tertiary referral lipid
clinic population. Each patient had been prescribed statin
monotherapy for management according to national dys-
lipidemia guidelines [15]. 133 subjects were statin-intol-
erant with myopathy, defined as having symptomatic
muscle weakness, tenderness and/or pain with at least one
of 1) medically advised discontinuation of statin medica-
tion on at least two occasions; 2) serum CK elevated to >3-
fold of the upper limit of normal while on a statin on at
least one occasion; and 3) medically diagnosed rhab-
domyolysis. Patients who only showed abnormal blood
biochemistry without symptomatic myalgia and/or
arthralgia were excluded. No patient was concurrently tak-
ing a fibric acid derivative, cyclosporine, macrolide antibi-
otic or antifungal agent. 158 clinic patients were matched
for sex and age within 5 years of statin-intolerant patients;
controls consisted of patients who had been on at least 10
mg of atorvastatin or rosuvastatin or 20 mg of other stat-
ins for ≥1 year with no reported symptoms and normal
serum CK concentration. When more than one subject
was suitable as control for a statin-intolerant patient, both
were included. In addition to collecting medication and
clinical data, determinations of serum C-reactive protein
at baseline and of serum CK, AST and ALT off- and on-
treatment were obtained.
DNA analysis
Genomic DNA was isolated from whole blood using the
Puregene DNA isolation kit (Gentra Systems Inc, Minne-
apolis, MN). SNP genotyping was performed using vali-
dated TaqMan genotyping assays purchased from Applied
Biosystems (ABI, Foster City, CA). Although several rarePublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Lipids in Health and Disease 2007, 6:7 http://www.lipidworld.com/content/6/1/7
Page 5 of 5
(page number not for citation purposes)
COQ2 SNPs have been identified, we chose to focus on
two SNPs that were most polymorphic and thus more
likely to serve as informative markers for the gene. SNP1
was a synonymous polymorphism in exon 5 (Assay ID
C_28947991_10, rs6535454). SNP2 was a non-coding
polymorphism in intron 4 (Assay ID C_28947992_10,
rs4693075). SNP genotyping was performed using an
allelic discrimination assay (TaqMan® SNP Genotyping
Assays, ABI, Foster City, CA) using the ABI Prism® 7900 HT
Sequence Detection System (SDS) and genotypes were
read using automated software (SDS 2.3, ABI, Foster City,
CA). Reactions were run in 5 uL volumes using an ampli-
fication protocol of 95°C for 10 minutes, followed by 50
cycles of 95°C for 15 seconds, then 60°C for 1.5 minutes.
Blinded replication of 5% of samples showed no discrep-
ancies between genotypes.
Statistical analyses
All analyses were performed using SAS version 9.0 (Cary,
NC), with a nominal level of significance defined as P <
0.05. Significance of the deviation of SNP genotype fre-
quencies from Hardy-Weinberg equilibrium was assessed
using chi-square analysis. Pairwise linkage disequilibrium
between COQ2 alleles was determined using correlation
coefficients as described [16]. Two-site maximal likeli-
hood haplotypes were constructed using PHASE version
2.0 [17]. Dominant and recessive genetic models of asso-
ciation of statin intolerance with either individual COQ2
SNP genotypes or COQ2 haplotype were evaluated using
chi-square analysis.
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